Rhythm Pharmaceuticals Inc.
- Address
- 222 Berkeley Street Floor 12th
Sponsor Overview
Specializations
Genetic obesity and appetite regulation disorders
Rhythm Pharmaceuticals Inc. focuses on conditions linked to impaired body weight and hunger control, with research centered on obesity driven by specific genetic variants affecting melanocortin pathway signaling.
- Setmelanotide in genetically defined obesity
- Body weight change
- Hunger regulation
The sponsor’s clinical activity is directed toward precision medicine approaches for patients whose obesity is associated with disrupted biological pathways controlling appetite and energy balance.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Setmelanotide in Obesity with POMC/PCSK1, LEPR, NCOA1, or SH2B1 Gene Variants |  France Germany Greece Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 14 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System and Oral Physiological Phenomena1 trial16 other sponsors
Partnered Research Centres
14 centres- Address
- Allee Des Topazes, Cs 11021, 97400 St Denis
- Address
- Hindenburgdamm 30, Lichterfelde, 12203 Berlin
- Address
- Dr. Molewaterplein 40, 3015 GD Rotterdam
- Address
- Rio, 265 04 Pátrai
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- 330 Avenue De Grande Bretagne, 31059 Toulouse
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Rhythm Pharmaceuticals Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.